DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TECFIDERA (dimethyl fumarate, BG-12, Fumaderm)
       *****************************************************
       #Post#: 774--------------------------------------------------
       (AAN) Risk of disease progression after starting Tecfidera...
   DIR By: agate
       Date: May 7, 2015, 3:04 pm
       ---------------------------------------------------------
       Presented at the recent annual AAN conference in Washington, DC:
       --- Quote ---
       > [P3.269] Risk of Disease Progression after Starting Dimethyl
       Fumurate (DMF): Data from the Providence Multiple Sclerosis
       Center’s DMF Registry
       >
       > Kyle Smoot, Kiren Kresa-Reahl, Chiayi Chen, Tamela Stuchiner,
       Bobbie Lee Roth, Stanley Cohan
       >
       > Portland, OR, USA.
       >
       > OBJECTIVE:
       >
       > To determine the risk of clinical relapses and MRI progression
       in patients treated with DMF [dimethyl fumarate = Tecfidera].
       >
       > BACKGROUND:
       >
       > Given the results of two Phase III trials and the greater
       convenience of an oral medication, we anticipated a strong
       interest in DMF. Because data concerning transition from prior
       disease modifying therapy to DMF is limited, a registry was
       established to monitor the utilization of DMF and the treatment
       outcomes.
       >
       > DESIGN/METHODS:
       >
       > Subjects prescribed DMF from March 2013 to September 2014 were
       identified. Charts are reviewed at the time of starting DMF and
       then every 6 months.
       >
       > RESULTS:
       >
       > 321 identified patients have been followed for a mean of 9.3
       months; 103 (32.1%) were previously treated with interferon beta
       (INFβ), 52 (16.2%) with glatiramer acetate (GA), 13 (4.0%)
       with fingolimod, 54 (16.8%) with natalizumab, 17 (5.3%) with
       other agents. 30 patients (9.3%) were newly diagnosed , and 52
       (16.2%) had been off prior treatment for at least 6 months
       before starting DMF.
       >
       > Clinical relapses occurred in 44 (13.7%) patients. Of those,
       18 (40.9%) of the relapses occurred within the first 3 months,
       10 ( 22.7%) between month 3 and 6, and 16 (36.4%) between month
       6 and 12 after starting DMF.
       >
       > MRI results are available from 171 (53.3%) patients, 143
       (83.6%) of which were stable.
       >
       > To date, 81 (25.2%) patients have stopped DMF including 27
       (8.4%) secondary to clinical or radiographic progression and 58
       (18.0%) secondary to side effects.
       >
       > CONCLUSIONS:
       >
       > The majority of relapses on DMF occurred within the first 3
       months after starting therapy. The risk of relapse was high in
       patients who were newly diagnosed (26.7%) and transitioning from
       natalizumab (18.5%). Mean washout period was 8 weeks for those
       who relapsed.
       >
       > Patients who previously were on fingolimod had a high rate of
       relapse; however, the number was relatively small, 4 (30.8%).
       >
       > ________________________
       > Category - MS and CNS Inflammatory Disease: Health
       Services/Outcomes Research
       >
       > Session: P3: Poster Session III: MS and CNS Inflammatory
       Diseases: Treatment Efficacy, Safety and Tolerability (2:00
       PM-6:30 PM)
       > Date/Time: Tuesday, April 21, 2015 - 2:00 pm
       --- End Quote ---
       The abstract can be seen here
  HTML http://www.abstracts2view.com/aan/view.php?nu=AAN15L1_P3.269&terms=.
       *****************************************************
       Page 1 of 1